ReviewCardiovascular diabetology2022

Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

Michael A Nauck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.